Drug
Ribociclib clinical trials
Also written LEE011 and Kisqali.
- studies test it
- 118
- open now
- 20
- in phase 3
- 18
- first study started
- 2010
Keep track of what changes. Save the ribociclib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
- Kisqali
- 31
Studies by the year they started
118 studies that test it; most in 2016 (20)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2013 | 7 |
| 2014 | 5 |
| 2015 | 15 |
| 2016 | 20 |
| 2017 | 11 |
| 2018 | 13 |
| 2019 | 8 |
| 2020 | 4 |
| 2021 | 5 |
| 2022 | 7 |
| 2023 | 6 |
| 2024 | 8 |
| 2025 | 3 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 3
- Phase 1
- 53
- Phase 2
- 55
- Phase 3
- 18
- Phase 4
- 5
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 51 · Other 67
Novartis Pharmaceuticals (38) · AstraZeneca (4) · Pfizer (3) · University of Michigan Rogel Cancer Center (2) · Fox Chase Cancer Center (2) · M.D. Anderson Cancer Center (2) · Prof. Wolfgang Janni (2) · Georgetown University (2)
Often tested with
Tested in the same studies.
Palbociclib (13) · Abemaciclib (13) · Fulvestrant (12) · Everolimus (11) · Letrozole (11) · Alpelisib (6) · Trametinib (5) · Paclitaxel (4)
Studies
Open first, then newest update. How each study uses ribociclib is read from its arms, and is right about nine times in ten.
Testing it · 118
- A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast CancerRecruitingPhase 3AstraZenecaNCT07647328Written as Ribociclib
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerRecruitingPhase 1/2Hoffmann-La RocheNCT03424005Written as Ribociclib (Dose #1)
- The CDK4/6 Inhibitor Dosing Knowledge (CDK) StudyRecruitingPhase 3American Society of Clinical OncologyNCT06377852Written as Ribociclib 600mg
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast CancerRecruitingPhase 1/2Hoffmann-La RocheNCT04802759Written as Ribociclib
- Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast CancerRecruitingPhase 2Northwestern UniversityNCT06062498Written as elacestrant, palbociclib, abemaciclib, ribociclib
- Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast CancerRecruitingPhase 3AstraZenecaNCT06380751Written as Ribociclib
- Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid TumorsRecruitingPhase 1/2Novartis PharmaceuticalsNCT06726148Written as ribociclib
- Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast CancerRecruitingPhase 2Oana DanciuNCT05467891Written as Ribociclib
- European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory TumorsRecruitingPhase 1/2Gustave Roussy, Cancer Campus, Grand ParisNCT02813135Written as Ribociclib
- A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.RecruitingPhase 2Centre Leon BerardNCT04116541Written as Ribociclib
- A Phase ll, Interventional, Single-arm Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib and Fulvestrant in Chinese Patients With PIK3CA-mutant, HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer.Not yet recruitingPhase 2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT07618390Written as Inavolisib + Ribociclib + Fulvestrant
- Efficacy and Safety of Camizestrant Plus Ribociclib in Patients With Breast CancerRecruitingPhase 2MedSIRNCT07195227Written as Ribociclib
- Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant ChemotherapyRecruitingPhase 3Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT07400523Written as Ribociclib plus aromatase inhibitor
- Ribociclib for HR-positive HER2-negative Metastatic Breast CancerRecruitingPhase 1/2Nagoya City UniversityNCT07164976Written as Ribociclib 400mg
- Fulvestrant With Ribociclib Versus Physician's Choice Treatments Recurred After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast CancerNot yet recruitingPhase 2Yeon Hee ParkNCT06849947Written as Ribociclib with fulvestrant
- Sequential Therapies Modeled on Evolutionary Dynamics for Breast CancerRecruitingPhase 2H. Lee Moffitt Cancer Center and Research InstituteNCT06409390Written as Ribociclib
- The Efficacy and Safety of CDK4/6 Inhibitors in Combination with Endocrine Therapy in the Neoadjuvant TreatmentNot yet recruitingNot applicableHongmei Zheng, PhDNCT06810492Written as Ribociclib; abemaciclib; palbociclib; Dalpiciclib
- T-DM1 Combined With CDK4/6 Inhibitor RibociclibEnrolling by invitationPhase 2Zheng YabingNCT06481956Written as Ribociclib Oral Tablet
- The Drug Rediscovery Protocol (DRUP Trial)RecruitingPhase 2The Netherlands Cancer InstituteNCT02925234Written as Ribociclib
- Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer PatientsRecruitingPhase 4Institut fuer FrauengesundheitNCT05452213Written as Ribociclib
See all 118 studies that test ribociclib →
Given in every arm · 35 — ribociclib is usual care beside what is tested
- Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low TrialRecruitingPhase 3National Cancer Institute (NCI)NCT07391774Written as Ribociclib Succinate
- The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical TrialsRecruitingPhase 4PfizerNCT05203172Written as Ribociclib
- A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)RecruitingPhase 3Eli Lilly and CompanyNCT07174336Written as Ribociclib
- A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast CancerRecruitingPhase 2Hoffmann-La RocheNCT07405801Written as Ribociclib
- Open-Label Study of BBO-10203 in Subjects With Advanced Solid TumorsRecruitingPhase 1TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)NCT06625775Written as Ribociclib
- Study of AVZO-021 in Patients With Advanced Solid TumorsRecruitingPhase 1/2Avenzo Therapeutics, Inc.NCT05867251Written as Ribociclib
- A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast CancerRecruitingPhase 2Hoffmann-La RocheNCT07054190Written as Ribociclib
- Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast CancerRecruitingPhase 3Olema Pharmaceuticals, Inc.NCT07085767Written as Ribociclib
- First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid TumorsRecruitingPhase 1/2Eli Lilly and CompanyNCT05768139Written as Ribociclib
- Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutantRecruitingPhase 2Nationwide Children's HospitalNCT05843253Written as Ribociclib
- Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine TherapyRecruitingPhase 2Yale UniversityNCT06953882Written as Ribociclib 400mg
- A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast CancerRecruitingPhase 1Totus MedicinesNCT05683418Written as Ribociclib
- ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast CancerNot yet recruitingPhase 2Fudan UniversityNCT07423611Written as Aromatase inhibitor (± ovarian suppression) plus Ribociclib
- A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BCRecruitingPhase 1/2Forward Pharmaceuticals Co., Ltd.NCT07002177Written as Ribociclib 200Mg Oral Tablet
- First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast CancerRecruitingPhase 1Relay Therapeutics, Inc.NCT05216432Written as Ribociclib 400mg
- A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid TumorsActive, not recruitingPhase 1/2AstraZenecaNCT06188520Written as Ribociclib
- Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C MutationTerminatedPhase 1/2Novartis PharmaceuticalsNCT05358249Written as Ribociclib
- Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)Active, not recruitingPhase 3AstraZenecaNCT04964934Written as Ribociclib
- A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)Active, not recruitingPhase 3Hoffmann-La RocheNCT06065748Written as Ribociclib
- Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALLActive, not recruitingPhase 1Dana-Farber Cancer InstituteNCT03740334Written as Ribociclib
Showing 20 of 35.
As the comparator · 8 — what is tested is compared with ribociclib
- BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic DiseaseRecruitingPhase 3BeOne MedicinesNCT07492641Written as Ribociclib
- Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)RecruitingPhase 3Celcuity IncNCT06757634Written as Arm B: Ribociclib + Fulvestrant
- Tolerability of Dalpiciclib vs. Abemaciclib/Ribociclib in Early HR+/HER2- Breast CancerNot yet recruitingNot applicableHenan Cancer HospitalNCT07706933Written as Abemaciclib/Ribociclib
- Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant RibociclibRecruitingPhase 3UNICANCERNCT07237256Written as Chemotherapy followed by endocrine therapy and ribociclib treatment
- Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast CancerRecruitingPhase 2Karolinska University HospitalNCT05900206Written as Ribociclib
- A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBCRecruitingPhase 2National Taiwan University HospitalNCT05766410Written as Ribociclib
- Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic DiseaseActive, not recruitingPhase 3PfizerNCT06760637Written as ribociclib
- Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or RibociclibTerminatedPhase 2UNICANCERNCT05625087Written as Ribociclib
Codes
What other systems call ribociclib · ClinicalTrials.gg INT000035
- MeSH (NLM) C000589651ribociclibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) TK8ERE8P56RIBOCICLIBConfirmed FDA, NLM, Wikidata
- RxNorm 1873916Confirmed FDA, Wikidata
- Wikidata Q27088552ribociclibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C95701RibociclibConfirmed FDA, Wikidata
- DrugBank DB11730One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000589651 | ribociclib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | TK8ERE8P56 | RIBOCICLIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1873916 | — | Confirmed FDA, Wikidata |
| Wikidata | Q27088552 | ribociclib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C95701 | Ribociclib | Confirmed FDA, Wikidata |
| DrugBank | DB11730 | — | One source Wikidata |
Also registered as ribociclib succinate (UNII BG7HLX2919 · RxNorm 1873978).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.